Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Huntington Disease →Neurological & Neuromuscular

AMT-130 (ifezuntirgene inilparvovec) for Huntington's disease

uniQure · BLA
FDA decision due
May 12027
165 days away
May has 6 FDA decisions on our calendar, this one included. Before it, Varegacestat on Apr 28th. After it, AXS-12 on May 1st.
Email me the day the FDA decides on AMT-130

One email when the decision is public, with what it means in plain language. You'll also get new trials and FDA news for Huntington Disease. Unsubscribe anytime.

You'll get, for Huntington Disease:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

The FDA is expected to decide on AMT-130 for Huntington's disease by May 1, 2027, under a BLA from uniQure.

What the FDA is deciding on AMT-130 for Huntington's disease

The FDA is reviewing uniQure's application to approve AMT-130 (ifezuntirgene inilparvovec) for Huntington's disease.

One-time gene therapy delivered by neurosurgery into the striatum to silence the huntingtin gene. uniQure says its Phase 1/2 data suggest it slows Huntington's disease; the FDA has not yet judged that claim, and no treatment is approved to slow the disease. On November 2, 2026 uniQure announced that the FDA accepted the BLA for priority review under the accelerated approval pathway, with a target action date of May 1, 2027.

The FDA told uniQure it is tentatively planning to discuss the application at an advisory committee meeting, and no meeting date has been set. The application rests on 36-month Phase 1/2 results compared with a matched outside group drawn from the Enroll-HD natural history study.

A confirmatory randomized trial of about 200 people, with Total Functional Capacity at 36 months as its main measure, is expected to begin screening in the US by the end of 2026. Holds Breakthrough Therapy, RMAT and Fast Track designations.

Who the AMT-130 decision matters to

Huntington disease is an autosomal dominant neurodegenerative disorder caused by an expanded CAG trinucleotide repeat in the huntingtin gene. The progressive disease causes movement problems, cognitive decline, and psychiatric symptoms.

Adult-onset disease typically appears ages 30-50, with juvenile-onset forms presenting earlier with different symptom profiles. Multiple disease-modifying therapies are in clinical trials.

Prevalence: About 3-7 per 100,000 people of European ancestry, according to MedlinePlus Genetics; less common in people of Japanese, Chinese and African descent. See our full Huntington Disease page for current treatments, recruiting trials, and community resources.

How AMT-130 works

AMT-130: one-time gene therapy that uses a harmless AAV5 virus shell to carry a microRNA into brain cells of the striatum, where it lowers production of the huntingtin protein. Our full AMT-130 profile covers how it works, side effects in plain language, and its trial history.

What an approval or a rejection of AMT-130 would mean

An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.

A complete response letter would mean the FDA declined to approve in the application's current form. The letter describes what the FDA wants addressed, and the company then decides whether to resubmit, run more studies or stop. Either way, this page updates with the outcome and what it means.

Where Huntington Disease treatment stands today

FDA approved for Huntington Disease (3)
Xenazine (tetrabenazine)VMAT2 inhibitorsince 2008Austedo (deutetrabenazine)VMAT2 inhibitorsince 2017Ingrezza (valbenazine)VMAT2 inhibitorsince 2023
Read our full Huntington Disease treatment summary

Huntington disease research is advancing 3 distinct approaches to lower mutant huntingtin levels. Antisense oligonucleotides (ASOs) like tominersen reduce HTT mRNA through intrathecal injection.

Gene therapies like AMT-130 use a viral vector to deliver a one-time genetic instruction to the brain that lowers production of the huntingtin protein. Splicing modifiers like votoplam (PTC518) are oral drugs that alter HTT pre-mRNA splicing.

Each approach has different trial designs and eligibility requirements. Genetic testing to confirm your CAG repeat length is the first step for any HD trial.

Premanifest gene carriers (CAG 40+ with no motor symptoms) have a growing number of prevention trials aimed at delaying or preventing symptom onset.

If you take fluoxetine, paroxetine, or bupropion for depression, check trial eligibility carefully, as these are strong CYP2D6 inhibitors excluded from some trials. Anyone taking one of these can ask their neurologist how it affects trial eligibility.

VMAT2 inhibitors for chorea are generally allowed at a stable dose.

The Huntington's Disease Society of America provides resources and genetic counseling referrals.

The Huntington Disease page has every treatment and trial →

Meanwhile, 44 Huntington Disease studies are recruiting or not yet recruiting

Whatever the FDA decides here, research on Huntington Disease does not stop. Of these, 28 test a treatment; the others follow patients over time. The most recently updated:

Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease
Treatment trial · NCT07378644 · has US sites
Pridopidine Phase 3 Study in Huntington's Disease
Treatment trial · NCT07609108 · has US sites
Multi-Modal Digital Monitoring of Disease Symptoms Huntington's Disease
Observational study, no treatment given · NCT07315984 · has US sites
See all 44 open studies →
Get an email the day the FDA decides on AMT-130

We'll email you when the decision is public, with what it means in plain language, and when new trials open for Huntington Disease. Unsubscribe anytime.

You'll get, for Huntington Disease:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Or get every FDA decision, for any condition

One email the day each decision on our calendar is announced, for any condition. No trial alerts and no condition to pick.

We never share your email. Stop anytime from the link in every email. Privacy policy

Frequently asked questions

When will the FDA decide on AMT-130?

The FDA's target date (PDUFA date) for AMT-130 in Huntington's disease is May 1, 2027.

Who disclosed it: uniQure. The FDA does not publish these dates.

Can it move: the FDA can act early, and a major amendment to the application can push the date back 3 months.

Source: uniQure press release, November 2, 2026

What is AMT-130 being reviewed for?

uniQure submitted a BLA for AMT-130 in Huntington's disease.

What to know: One-time gene therapy delivered by neurosurgery into the striatum to silence the huntingtin gene. uniQure says its Phase 1/2 data suggest it slows Huntington's disease; the FDA has not yet judged that claim, and no treatment is approved to slow the disease. On November 2, 2026 uniQure announced that the FDA accepted the BLA for priority review under the accelerated approval pathway, with a target action date of May 1, 2027. The FDA told uniQure it is tentatively planning to discuss the application at an advisory committee meeting, and no meeting date has been set. The application rests on 36-month Phase 1/2 results compared with a matched outside group drawn from the Enroll-HD natural history study. A confirmatory randomized trial of about 200 people, with Total Functional Capacity at 36 months as its main measure, is expected to begin screening in the US by the end of 2026. Holds Breakthrough Therapy, RMAT and Fast Track designations.

How it works: One-time gene therapy that uses a harmless AAV5 virus shell to carry a microRNA into brain cells of the striatum, where it lowers production of the huntingtin protein.

More: the AMT-130 drug page explains it in plain language.

Is there already an FDA-approved treatment for Huntington Disease?

Yes. Trial Friend's drug list includes 3 FDA-approved drugs for Huntington Disease.

Approved: Xenazine (tetrabenazine), Austedo (deutetrabenazine), Ingrezza (valbenazine).

Check: the Huntington Disease page also searches FDA drug labels for approved treatments.

What did the AMT-130 trials show?

The US Phase 1/2 study (NCT04120493) began on September 6, 2019 at 12 US sites and enrolls adults aged 25 to 65 with early Huntington's disease, 40 or more CAG repeats in the HTT gene and a Total Functional Capacity score of 9 to 13 in most cohorts. uniQure says the randomized part of the US study enrolled 26 people, including a group that had a sham procedure, in which surgeons make skin incisions but do not drill into the skull; a later cohort of 12 received either dose with immune-dampening medicines, and a fourth cohort of 6 is testing the high dose in people with smaller striatal volumes. A European open-label study (NCT05243017) enrolled 13 people, according to uniQure; ClinicalTrials.gov lists 14.

More: the AMT-130 drug page has the full trial history and sources.

What are the side effects of AMT-130?

AMT-130 has no FDA label, so its official side effects and warnings are not set. uniQure reported on September 29, 2026 that the therapy was generally well tolerated at both doses, that the most common side effects were related to the surgical procedure used to give it, and that all of these had resolved. In the same release uniQure said 5 high-dose participants had a serious side effect related to treatment involving inflammation of the brain and spinal cord, all of which fully resolved. uniQure also reported that 1 person in a low-dose group died by suicide about 5 years after treatment, a death the study investigator assessed as unrelated to treatment. uniQure's November 4, 2026 update described the safety profile as manageable across all 51 people treated so far.

More: the AMT-130 drug page has the safety details reported so far.

Can I get AMT-130 before the FDA decides?

Usually only through a clinical trial or an expanded access program, and the company decides whether to offer one.

Trials: 44 Huntington Disease studies are recruiting or not yet recruiting, 28 of them testing a treatment. See them.

Check your fit: Match Me compares your details with every open trial.

Expanded access: your doctor can ask uniQure directly. Registered programs are listed on ClinicalTrials.gov.

How much will AMT-130 cost?

uniQure has not announced a price. Drugmakers usually set it around approval.

Help paying: drugmaker programs and charity funds usually open at launch.

Find help: the patient assistance finder lists programs by insurance type.

What happens after the AMT-130 decision?

This page updates with the outcome the day it is announced.

If approved: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.

If not approved: a complete response letter means the FDA declined the application in its current form. Many are about manufacturing or how data were presented, and companies often resubmit.

Where this date comes from

The FDA does not publish PDUFA dates; companies disclose them. This one comes from uniQure press release, November 2, 2026. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.